Serum Uromodulin â€ A Potential Biomarker to Predict Response to Lupus Nephritis Treatment in Adults

Renal Division, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University0 sites43 target enrollmentOctober 2, 2018

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Active lupus nephritis
Sponsor: Renal Division, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University
Enrollment: 43
Status: Recruiting
Last Updated: last year

No summary available.

Registry

who.int

Start Date

October 2, 2018

End Date

January 4, 2019

Last Updated

last year

Study Type

Observational

Sex

All

Sponsor

Renal Division, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University

•1\. Age of 18 or older
•2\. Diagnosed systemic lupus erythematosus (SLE) according to 1997 American College of Rheumatology (ACR) criteria
•3\. Patients with active lupus nephritis requiring induction therapy according to physician opinion. However, kidney biopsy to confirm lupus nephritis is not required. Active lupus nephritis is defined as one of the following:
•3\.1 Presence of urine protein of more than 0\.5 gram per day and presence of red blood cells (RBC) in urine of more than 5 cells per high power field or presence of RBC cast or
•3\.2 Presence of urine protein of more than 3\.0 gram per day if RBC in the urine less than 5 cells per high power field and no RBC cast
•3\.3 If kidney biopsy was done, presence of the evidence of active lupus nephritis class III, IV or V according to the 2003 International Society for Nephrology/Renal Pathology Society (ISN/RPS) classification criteria

•1\. Pregnancy
•2\. Patients with antiphospholipid syndrome (APS)
•3\. Patients with thrombotic thrombocytopenic purpura (TTP)
•4\. Patients with overlapping syndrome
•5\. Patients who have estimated glomerular filtration rate (eGFR) less than 30 ml/min/1\.73 m2\.